Key result
Combining imaging techniques with biomarkers represents a promising path for the early detection of cardiotoxicity under monoclonal antibodies therapy.
Why the study?
Cancer therapies reduce mortality but frequently cause adverse cardiovascular effects, making cardiac monitoring essential to increase lifelong expectancy.
Does combining echocardiography with biomarkers improve the early detection of cardiotoxicity in cancer patients receiving monoclonal antibodies?
Does combining echocardiography with biomarkers improve the early detection of cardiotoxicity in cancer patients receiving monoclonal antibodies?
Answers are grounded in this paper and cite their sources.
Combining echocardiographic strain analysis with biomarkers is a promising strategy for the early detection of cardiotoxicity in cancer patients on monoclonal antibody therapy.
The progress made over the past years in the field of cancer therapy has led to a significant decrease in cancer mortality, but these therapies have many adverse effects, cardiovascular effects being among the most frequent ones. For increasing lifelong expectancy of surviving cancer patients, cardiac monitoring represents an important task. Current studies and practice recommend echocardiography using strain analysis for monitoring the cardio toxic effects of cancer therapy. The potential of combining imaging techniques with biomarkers for the early detection and diagnosis seems a promising path for future research.
No takes yet. Share an insight, caveat, or question.
Popovici et al. (2021) conducted a review in Cancer therapy-induced cardiotoxicity. Echocardiography and biomarkers was evaluated. Combining imaging techniques with biomarkers represents a promising path for the early detection of cardiotoxicity under monoclonal antibodies therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: